Acura Pharmaceuticals Company Description
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States.
It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products.
Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology.
The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois.
Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.
| Country | United States |
| Founded | 1935 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Robert Jones |
Contact Details
Address: 616 N. North Court Palatine, New York 60067 United States | |
| Phone | 847 705 7709 |
| Website | acurapharm.com |
Stock Details
| Ticker Symbol | ACUR |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US00509L8028 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert B. Jones | Chief Executive Officer, President and Director |
| Robert A. Seiser CPA, Ph.D. | Chief Financial Officer, Senior Vice President, Treasurer and Corporate Controller |